Stay updated with breaking news from லூக் சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Saniona AB: Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction January 25, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received approximately USD $2.9 million (SEK 24.2 million) in an upfront payment resulting from the now completed acquisition of Cadent Therapeutics by a third party. Saniona holds an ownership stake of approximately 3% in Cadent Therapeutics resulting from Cadent s previous acquisition of the Saniona spin-out Ataxion, which was created to leverage Saniona s ion channel expertise for the treatment of movement disorders. Saniona previously announced the planned acquisition and its ownership stake in December 2020. ....
Slater Technology Fund-backed company to be acquired by Novartis A SLATER TECHNOLOGY FUND-backed company, Cadent Therapeutics, has entered into an agreemnt to be acquired by Novartis in a deal worth up to $770 million. PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology Fund-backed company Mnemosyne Pharmaceuticals. Mnemosyne developed a drug-discovery program targeting the creation of… Register to keep reading or subscribe today and receive unlimited access. ....
Saniona AB: Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3% December 17, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it was informed that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%. The financial impact of this potential acquisition to Saniona is not known at this time. Novartis and Cadent each announced today that Novartis intends to acquire all of the outstanding capital stock of Cadent. Upon the closing of the transaction, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $770 million. Saniona holds an ownership stake of approximately 3% in Cadent resulting from Cadent s previous acquisition of the Saniona spin-out Ataxion, which was cr ....
Novartis to Acquire Cadent Therapeutics for Up to $770 Million Share Rare Daily Staff Novartis is adding to its neuroscience pipeline by acquiring Cadent Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, including its program for the treatment of spinocerebellar ataxia. Under the terms of the acquisition, Novartis will pay Cadent $210 million upfront and potentially up to $560 million in milestone payments. Cadent Therapeutics launched in 2017 through the merger of Luc Therapeutics and Ataxion Therapeutics, with a focus on small molecules targeting neuronal ion channels. The deal gives Novartis full rights to Cadent’s neuroscience portfolio, including its NMDAr program, which consists of two clinical programs: CAD-9303, a NMDAr positive allosteric modulator, and MIJ-821, a NMDAr negative allosteric modulator, which wa ....
Novartis to buy neuroscience firm Cadent Therapeutics for up to $770m pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.